ExploRNACap analogsAvantCap Q1
Product details
Extinction Coefficient 46 100 M-1 cm-1 at 260nm
Molecular weight (free acid) 1565.0 g/mol
Molecular formula (free acid) C49H61N20O30P5
Salt Na+
Form 100 mM water solution at pH 6.5

AvantCap Q1

Delivers high yields and capping efficiencies across a wide range of IVT conditions

Highlights

  • Proprietary Intellectual Property
  • Nature-inspired design for improved biological properties
  • Compatible with variety of IVT conditions
  • High transcription yield and capping efficiency
  • High-quality final mRNA product due to lower dsRNA content comparing to mRNA with natural Cap 1 analog
  • Outstanding in vivo performance in multiple experimental settings in the presence and absence of RNA body modifications
  • Possibility of fine-tuning mRNA quality – access to ultrapure mRNA by hydrophobic handle-assisted HPLC purification

We are proud to introduce a new line of ExploRNA’s cap analogs: AvantCap® Q – an innovative solution designed to simplify and boost your IVT process.

AvantCap® is the name of our flagship product, featuring unique benzyl modification that enhances its biological properties. Q stands for Quatre – tetranucleotide cap analogs facilitating better alignment with the DNA template ensuring high capping efficiency.

AvantCap® Q offers both, Cap 1 (AvantCap® Q1) and Cap 2 (AvantCap® Q2) versions, tailored to meet your specific needs.

 

Promoter compatibility

AvantCap® Q1 is fully compatible with plasmid templates containing T7 polymerase φ6.5 promoter starting with AG.

AvantCap® Q1: Biological activity in in vitro settings

mRNA: firefly luciferase; unmodified U | Transfection: Lipofectamine | Timepoint: 24 h | Caps: Cap1, AvantCap variants
Cell types: HEK293T, human and murine macrophages

 

AvantCaps® Q1 provides enhanced mRNA activity in vivo

mRNA: human EPO; unmodified U | Dose: 1 µg | Caps: AvantCap variants and their unmodified analogs | LNP: clinical grade | Administration: intravenous

 

AvantCap® Q1 is compatible with mRNA body modifications and different purification pipelines

mRNA: human EPO; unmodified U
Dose: 1µq
LNPs: Clinical grade
Purification: Affinity resin + HPLC

mRNA: human EPO; N1-MeΨ
Dose: 1µq
LNPs: Clinical grade
Purification: Affinity resin